Drug profile · INN
capmatinib hydrochloride
TABRECTA
capmatinib hydrochloride (TABRECTA) is a hepatocyte growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — capmatinib hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
capmatinib hydrochloride (TABRECTA) is a hepatocyte growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Hepatocyte growth factor receptor inhibitor
Primary target: Hepatocyte growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is capmatinib hydrochloride?
capmatinib hydrochloride (TABRECTA) is a hepatocyte growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for capmatinib hydrochloride?
TABRECTA is a marketed brand name for capmatinib hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of capmatinib hydrochloride?
capmatinib hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.